223 related articles for article (PubMed ID: 7038095)
1. Assessment of the extent to exogenous prostaglandin I2 is converted to 6-keto-prostaglandin E1 in human subjects.
Jackson EK; Goodman RP; Fitzgerald GA; Oates JA; Branch RA
J Pharmacol Exp Ther; 1982 Apr; 221(1):183-7. PubMed ID: 7038095
[TBL] [Abstract][Full Text] [Related]
2. 6-Keto-prostaglandin E1 is more potent than prostaglandin I2 as a renal vasodilator and renin secretagogue.
Jackson EK; Herzer WA; Zimmerman JB; Branch RA; Oates JA; Gerkens JF
J Pharmacol Exp Ther; 1981 Jan; 216(1):24-7. PubMed ID: 7005428
[TBL] [Abstract][Full Text] [Related]
3. 6-Keto-prostaglandin E1 is a potent coronary vasodilator and stimulates a vagal reflex in dogs.
Panzenbeck MJ; Hintze TH; Kaley G
J Pharmacol Exp Ther; 1988 Mar; 244(3):814-9. PubMed ID: 3075239
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the effects of prostacyclin and 6-keto-prostaglandin E1 on renin release in the isolated rat and rabbit kidney.
Schwertschlag U; Stahl T; Hackenthal E
Prostaglandins; 1982 Jan; 23(1):129-38. PubMed ID: 7038776
[TBL] [Abstract][Full Text] [Related]
5. Single-blind study of epoprostenol and 6-keto-prostaglandin E1 in man: effects of platelet aggregation and plasma renin.
Miyamori I; Morise T; Yasuhara S; Takeda Y; Koshida H; Takeda R
Br J Clin Pharmacol; 1985 Dec; 20(6):681-3. PubMed ID: 3912001
[TBL] [Abstract][Full Text] [Related]
6. Elimination from the circulation of cats of 6-keto-prostaglandin E1 compared with prostaglandins E2 and I2.
Förstermann U; Neufang B
J Pharm Pharmacol; 1983 Nov; 35(11):724-8. PubMed ID: 6139453
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the pulmonary, hepatic and renal extraction of PGI2 and 6-keto-PGE1.
Tsunoda S; Jackson EK; Branch RA; Gerkens JF
Eur J Pharmacol; 1982 Jan; 77(2-3):147-51. PubMed ID: 7037431
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of prostacyclin: formation of an active metabolite in the liver.
Wong PY; Lee WH; Quilley CP; McGiff JC
Fed Proc; 1981 May; 40(7):2001-4. PubMed ID: 7014260
[TBL] [Abstract][Full Text] [Related]
9. The effect of intravitreal and topical prostaglandins on intraocular inflammation.
Kulkarni PS; Srinivasan BD
Invest Ophthalmol Vis Sci; 1982 Sep; 23(3):383-92. PubMed ID: 7050005
[TBL] [Abstract][Full Text] [Related]
10. A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics.
Bothwell W; Verburg M; Wynalda M; Daniels EG; Fitzpatrick FA
J Pharmacol Exp Ther; 1982 Feb; 220(2):229-35. PubMed ID: 6948952
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of prostacyclin and 6-keto-prostaglandin F1 alpha in man.
Rosenkranz B; Fischer C; Reimann I; Weimer KE; Beck G; Frölich JC
Artery; 1980; 8(1):18-22. PubMed ID: 7000039
[TBL] [Abstract][Full Text] [Related]
12. Identification of 6-keto-prostaglandin E1 obtained from isolated perfused kidney of the rabbit.
Pieroni JP; Dray F; Pace-Asciak CR; McGiff JC
J Pharmacol Exp Ther; 1988 Oct; 247(1):63-8. PubMed ID: 3139870
[TBL] [Abstract][Full Text] [Related]
13. Vasodilator actions of prostaglandin 6-keto-E1 in the pulmonary vascular bed.
Hyman AL; Kadowitz PJ
J Pharmacol Exp Ther; 1980 Jun; 213(3):468-72. PubMed ID: 7193724
[TBL] [Abstract][Full Text] [Related]
14. 6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent.
Miller OV; Aiken JW; Shebuski RJ; Gorman RR
Prostaglandins; 1980 Aug; 20(2):391-400. PubMed ID: 6251513
[TBL] [Abstract][Full Text] [Related]
15. Metabolic disposition of prostacyclin in humans.
Brash AR; Jackson EK; Saggese CA; Lawson JA; Oates JA; FitzGerald GA
J Pharmacol Exp Ther; 1983 Jul; 226(1):78-87. PubMed ID: 6345756
[TBL] [Abstract][Full Text] [Related]
16. Placental vascular responses to 6-keto-prostaglandin E1 in the near-term sheep.
Schwartz DB; Phernetton TM; Stock MK; Rankin JH
Am J Obstet Gynecol; 1983 Feb; 145(4):406-10. PubMed ID: 6337494
[TBL] [Abstract][Full Text] [Related]
17. [Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease].
Hesse WH; Rudofsky G; Peskar BA
Wien Klin Wochenschr; 1991; 103(18):554-7. PubMed ID: 1750222
[TBL] [Abstract][Full Text] [Related]
18. Effects of the prostacyclin products, 6-keto prostaglandin E1 and 6-keto prostaglandin F1 alpha, on bone resorption in vitro.
Neuman SD; Raisz LG
Prostaglandins Leukot Med; 1984 Jul; 15(1):103-8. PubMed ID: 6382342
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietic effects of prostacyclin (PGI2) and its metabolite 6-keto-prostaglandin (PG)E1.
Nelson PK; Brookins J; Fisher JW
J Pharmacol Exp Ther; 1983 Aug; 226(2):493-9. PubMed ID: 6410047
[No Abstract] [Full Text] [Related]
20. Conversion of prostacyclin to 6 oxo prostaglandin E1 by rat, rabbit, guinea-pig and human platelets.
Griffiths RJ; Moore PK
Br J Pharmacol; 1983 Oct; 80(2):395-402. PubMed ID: 6360281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
